feedback

Course Director

Robert Dreicer,  MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCO

University of Virginia Cancer Center
University of Virginia School of Medicine
Charlottesville, Virginia

Faculty

Arjun Balar
Arjun Balar, MD

NYU Perlmutter Cancer Center
New York, New York

Jonathan E. Rosenberg
Jonathan E. Rosenberg, MD

Memorial Sloan Kettering Cancer Institute
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Mar-16
Expiration Date:2018-Mar-15
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

For medical and urologic oncologists, the use of immune checkpoint inhibitors represents a new, unique weapon in the ongoing fight against advanced bladder cancer, in a setting where therapeutic progress has been modest over the past 40 years. Clinicians now have the opportunity to translate the emerging science around immunotherapy in patients with bladder cancer into daily practice, and engage with their patients on the potential benefits and practical aspects of treatment with novel immune-based agents.

In this activity based on the 2017 Genitourinary Cancers Symposium (ASCO-GU 2017) in Orlando, Florida, a panel of experts provides insight on the validation of immunotherapy in bladder cancer and strategies for applying the science on checkpoint blockade to clinical practice; in addition, the experts will offer their perspectives and advice on how to involve patients in their own care as the era of immunotherapy for bladder cancer begins in earnest.

Upon completion of this activity, participants should be better able to:
  • Describe the mechanism of action and underlying biologic rationale for the use of immune checkpoint inhibitors in bladder cancer
  • Discuss the clinical role of immune checkpoint inhibitors, including the latest efficacy and safety findings, in patients with advanced urothelial carcinoma
  • Recommend immune checkpoint blockade therapies for eligible patients with bladder cancer, with considerations of patient and disease characteristics, benefits and risks of therapy, and patient preferences
  • Employ appropriate strategies to optimally monitor for and manage immune-mediated adverse events in patients receiving immune checkpoint blockade therapies

Target Audience

The activity has been designed to meet the educational needs of oncologists, urologists, and other clinicians involved in the management of patients with bladder cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 16, 2017 - March 15, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Asana BioSciences, LLC.; Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Pfizer Inc./EMD Serono, Inc.; and sanofi-aventis U.S. LLC./Genzyme Corporation, a Sanofi company.

Robert Dreicer, MD, MS, MACP, FASCO, does intend to discuss either non–FDA approved or investigational use for the following products/devices: novel checkpoint inhibitors including atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab, among other checkpoint inhibitors in a variety of urothelial carcinoma settings.

Faculty

Arjun Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center
New York, New York

Arjun Balar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Grant/Research Support from Genentech, Inc./F. Hoffmann-La Roche Ltd. and Merck & Co., Inc.
Honoraria from AstraZeneca/MedImmune and Merck & Co., Inc.
Advisory Board for AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.

Arjun Balar, MD, does intend to discuss either non–FDA approved or investigational use for the following products/devices: novel checkpoint inhibitors including atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab, among other checkpoint inhibitors in a variety of urothelial carcinoma settings.

Jonathan E. Rosenberg, MD
Medical Oncologist
Enno W. Ercklentz Chair
Harvard Medical School
Memorial Sloan Kettering Cancer Institute
New York, New York

Jonathan E. Rosenberg, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Agensys, Inc.; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; EMD Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.
Grant/Research Support from Genentech, Inc./F. Hoffmann-La Roche Ltd. and Novartis Pharmaceuticals Corporation.
Other Financial or Material Support from Illumina, Inc. and Merck & Co., Inc. in the form of stock options.

Jonathan E. Rosenberg, MD, does intend to discuss either non–FDA approved or investigational use for the following products/devices: novel checkpoint inhibitors including atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab, among other checkpoint inhibitors in a variety of urothelial carcinoma settings.

CME Reviewer

Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York

Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Genentech.

Collaboration Statement

This CME activity has been developed in collaboration with the Bladder Cancer Advocacy Network.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.